You are here

  • Home
  • Archive
  • Volume 54, Issue 11
  • Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment

Citation Tools

Article menu

Download PDFPDF

Therapeutics
Original article
Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Mauer M, Sokolovskiy A, Barth JA, et al
Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
Journal of Medical Genetics 2017;54:781-786.